Keppra (Levetiracetam) Level
| Abbrev Code: | LEV | ||
| Order Code: | LAB6972 | Order Name: | Keppra (Levetiracetam) Level |
| Methodology: | ARK homogeneous enzyme immunoassay | ||
| CPT Codes: | 80177 x1, 80177 x1 | ||
| Turnaround Time: | Performed and reported daily. | ||
| Associated Links: | |||
Collection Instructions
| Specimen: | Blood |
| Optimal Volume: | 2.5 mL |
| Minimum\Peds Volume: | 0.6 mL |
| Container: | Red (no gel) Alternate Containers: Purple (EDTA) |
| Collection Instructions: | Timing of specimen collection: Predose (trough) draw - At steadty state concentration. |
| Causes for Rejection: | Serum or plasma separator tubes. Grossly hemolyzed specimens. |
Processing and Shipping
| Specimen Processing: | Centrifuge and aliquot serum or plasma from cells ASAP or within 2 hours of collection. Aliquot 1 mL, 0.3 mL minimum. Store in refrigerator. |
| Shipping Instructions: | Ship at refrigerated temperature. |
| Stability: | Roche: After separation from cells: 1 week refrigerated; 1 month frozen. |
| Test Performed at or Referral Lab | Chemistry (Roche-UMMC East) |
Interpretive
| Critical Range: | Toxic: Not well established. |
| Therapeutic Range: | 10-40 μg/mL
Interpretive Data: Pharmacokinetics of levetiracetam are affected by renal function. Adverse effects may include somnolence, weakness, headache and vomiting. This levetiracetam (Keppra) immunoassay uses the ARK Diagnostics reagents, which has known cross-reactivity with the drug brivaracetam (Briviact) and may report inaccurate results. Patients transitioning from levetiracetam to brivaracetam or those who are using both medications should not monitor drug concentrations with the ARK Diagnostics assay. These patients should be monitored using a validated chromatographic methodology that distinguishes between drugs to determine drug concentrations. |
Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 3734"